TY - JOUR
T1 - Clinical triage of patients on kidney replacement therapy presenting with COVID-19
T2 - An ERACODA registry analysis
AU - Mitra, Sandip
AU - Jayanti, Anuradha
AU - Vart, Priya
AU - Coca, Armando
AU - Gallieni, Maurizio
AU - Øvrehus, Marius Altern
AU - Midtvedt, Karsten
AU - Abd Elhafeez, Samar
AU - Gandolfini, Iliaria
AU - Büttner, Stefan
AU - Franssen, Casper F.M.
AU - Hemmelder, Marc H.
AU - Van Der Net, Jeroen B.
AU - Essig, Marie
AU - Du Buf-Vereijken, Peggy W.G.
AU - Van Ginneken, Betty
AU - Maas, Nanda
AU - Vogt, Liffert
AU - Van Jaarsveld, Brigit C.
AU - Jager, Kitty J.
AU - Bemelman, Frederike J.
AU - Klingenberg-Salahova, Farah
AU - Heenan-Vos, Frederiek
AU - Vervloet, Marc G.
AU - Nurmohamed, Azam
AU - Abramowicz, Daniel
AU - Verhofstede, Sabine
AU - Maoujoud, Omar
AU - Malfait, Thomas
AU - Fialova, Jana
AU - Melilli, Edoardo
AU - Favà, Alexandre
AU - Cruzado, Josep M.
AU - Perez, Nuria Montero
AU - Lips, Joy
AU - Krepel, Harmen
AU - Adilovic, Harun
AU - Hengst, Maaike
AU - Rydzewski, Andrzej
AU - Gellert, Ryszard
AU - Oliveira, João
AU - Alferes, Daniela G.
AU - Zakharova, Elena V.
AU - Ambuehl, Patrice Max
AU - Walker, Andrea
AU - Winzeler, Rebecca
AU - Lepeytre, Fanny
AU - Abrahams, Alferso C.
AU - Van Zuilen, Arjan D.
AU - Meijvis, Sabine C.A.
N1 - Funding Information:
ERACODA received unrestricted research grants from the ERA-EDTA, the Dutch Kidney Foundation, Baxter and Sandoz.
Publisher Copyright:
© 2021 The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Background: Patients on kidney replacement therapy (KRT) are at very high risk of coronavirus disease 2019 (COVID-19). The triage pathway for KRT patients presenting to hospitals with varying severity of COVID-19 illness remains ill-defined. We studied the clinical characteristics of patients at initial and subsequent hospital presentations and the impact on patient outcomes. Methods: The European Renal Association COVID-19 Database (ERACODA) was analysed for clinical and laboratory features of 1423 KRT patients with COVID-19 either hospitalized or non-hospitalized at initial triage and those re-presenting a second time. Predictors of outcomes (hospitalization, 28-day mortality) were then determined for all those not hospitalized at initial triage. Results: Among 1423 KRT patients with COVID-19 [haemodialysis (HD), n = 1017; transplant, n = 406), 25% (n = 355) were not hospitalized at first presentation due to mild illness (30% HD, 13% transplant). Of the non-hospitalized patients, only 10% (n = 36) re-presented a second time, with a 5-day median interval between the two presentations (interquartile range 2-7 days). Patients who re-presented had worsening respiratory symptoms, a decrease in oxygen saturation (97% versus 90%) and an increase in C-reactive protein (26 versus 73 mg/L) and were older (72 vs 63 years) compared with those who did not return a second time. The 28-day mortality between early admission (at first presentation) and deferred admission (at second presentation) was not significantly different (29% versus 25%; P = 0.6). Older age, prior smoking history, higher clinical frailty score and self-reported shortness of breath at first presentation were identified as risk predictors of mortality when re-presenting after discharge at initial triage. Conclusions: This study provides evidence that KRT patients with COVID-19 and mild illness can be managed effectively with supported outpatient care and with vigilance of respiratory symptoms, especially in those with risk factors for poor outcomes. Our findings support a risk-stratified clinical approach to admissions and discharges of KRT patients presenting with COVID-19 to aid clinical triage and optimize resource utilization during the ongoing pandemic.
AB - Background: Patients on kidney replacement therapy (KRT) are at very high risk of coronavirus disease 2019 (COVID-19). The triage pathway for KRT patients presenting to hospitals with varying severity of COVID-19 illness remains ill-defined. We studied the clinical characteristics of patients at initial and subsequent hospital presentations and the impact on patient outcomes. Methods: The European Renal Association COVID-19 Database (ERACODA) was analysed for clinical and laboratory features of 1423 KRT patients with COVID-19 either hospitalized or non-hospitalized at initial triage and those re-presenting a second time. Predictors of outcomes (hospitalization, 28-day mortality) were then determined for all those not hospitalized at initial triage. Results: Among 1423 KRT patients with COVID-19 [haemodialysis (HD), n = 1017; transplant, n = 406), 25% (n = 355) were not hospitalized at first presentation due to mild illness (30% HD, 13% transplant). Of the non-hospitalized patients, only 10% (n = 36) re-presented a second time, with a 5-day median interval between the two presentations (interquartile range 2-7 days). Patients who re-presented had worsening respiratory symptoms, a decrease in oxygen saturation (97% versus 90%) and an increase in C-reactive protein (26 versus 73 mg/L) and were older (72 vs 63 years) compared with those who did not return a second time. The 28-day mortality between early admission (at first presentation) and deferred admission (at second presentation) was not significantly different (29% versus 25%; P = 0.6). Older age, prior smoking history, higher clinical frailty score and self-reported shortness of breath at first presentation were identified as risk predictors of mortality when re-presenting after discharge at initial triage. Conclusions: This study provides evidence that KRT patients with COVID-19 and mild illness can be managed effectively with supported outpatient care and with vigilance of respiratory symptoms, especially in those with risk factors for poor outcomes. Our findings support a risk-stratified clinical approach to admissions and discharges of KRT patients presenting with COVID-19 to aid clinical triage and optimize resource utilization during the ongoing pandemic.
KW - COVID-19
KW - Dialysis
KW - Kidney
KW - Mortality
KW - Second presentation
KW - Transplantation
UR - http://www.scopus.com/inward/record.url?scp=85121359140&partnerID=8YFLogxK
U2 - 10.1093/ndt/gfab196
DO - 10.1093/ndt/gfab196
M3 - Article
C2 - 34129039
AN - SCOPUS:85121359140
SN - 0931-0509
VL - 36
SP - 2308
EP - 2320
JO - Nephrology Dialysis Transplantation
JF - Nephrology Dialysis Transplantation
IS - 12
ER -